Ghost Tree Capital, LLC Avadel Pharmaceuticals PLC Transaction History

Ghost Tree Capital, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 16, 2021	SELL	$5.03 - $7.95 $4.15 Million - $6.56 Million	-825,000 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$7.25 - $11.75 $3.44 Million - $5.58 Million	475,000 Added 135.71%	825,000 $6.67 Million
Q1 2020 May 15, 2020	BUY	$4.06 - $10.64 $1.42 Million - $3.72 Million	350,000 New	350,000 $2.78 Million
Q4 2018 Feb 14, 2019	SELL	$1.74 - $4.66 $783,000 - $2.1 Million	-450,000 Closed	0 $0
Q2 2018 Aug 14, 2018	SELL	$5.89 - $7.78 $2.36 Million - $3.11 Million	-400,000 Reduced 47.06%	450,000 $2.76 Million
Q1 2018 May 15, 2018	BUY	$6.76 - $11.7 $5.75 Million - $9.95 Million	850,000 New	850,000 $6.2 Million

1.07M

Ticker AVDL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 60,581,300
Market Cap $661M
Description
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...

Get notified when there are updates to the investment portfolio of Ghost Tree Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Ghost Tree Capital, LLC with notifications on news.